Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms

Trends in Cardiovascular Medicine
Réjane Paumelle, Bart Staels

Abstract

Although a change in lifestyle is the first choice in controlling cardiovascular risk, lipid-lowering drugs are effective in normalizing different forms of atherogenic dyslipidemia. Although statins are a class of drugs which primarily lower low-density lipoprotein cholesterol, fibrates decrease triglycerides, normalize the low-density lipoprotein cholesterol profile, and increase high-density lipoprotein cholesterol. As lipids are important determinants for cardiovascular diseases, these drugs reduce cardiovascular morbidity. However, a number of recent studies indicate that, in addition to their lipid-normalizing activities, statins and fibrates exhibit pleiotropic actions, such as inhibit inflammation, improve endothelial function, suppress the production of reactive oxygen species, etc. Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme of cholesterol synthesis, whereas fibrates are activators of the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha). The similarity between the pleiotropic effects of statins and fibrates is remarkable and suggests a mechanistic link between these two classes of drugs. Here we discuss recent data on the c...Continue Reading

References

Sep 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·M S Brown, J L Goldstein
Jul 17, 2001·European Journal of Clinical Investigation·A AvogaroS Del Prato
Oct 9, 2002·Trends in Pharmacological Sciences·Gabriele Weitz-Schmidt
Feb 8, 2005·The American Journal of Cardiology·Scott M GrundyJoanne Palmisano
Apr 20, 2005·Journal of the American College of Cardiology·Rainer Schulz
May 17, 2005·Journal of the American College of Cardiology·Kwang Kon KohEak Kyun Shin

❮ Previous
Next ❯

Citations

Sep 26, 2009·Evidence-based Complementary and Alternative Medicine : ECAM·Lisa M AllevaIan A Clark
Dec 24, 2009·Canadian Journal of Physiology and Pharmacology·Tána RavingerováAntigone Lazou
Aug 13, 2009·Journal of Atherosclerosis and Thrombosis·Atsushi NoharaHiroshi Mabuchi
Sep 10, 2009·Journal of Lipid Research·Jason S TrouttRobert J Konrad
Dec 17, 2009·BMC Genomics·Duccio CavalieriMichael Müller
Jul 9, 2013·Antiviral Research·David S Fedson
Feb 18, 2016·Scientific Reports·Alexandra MontagnerWalter Wahli
Apr 2, 2011·Expert Review of Cardiovascular Therapy·Nkechinyere Ijioma, Jennifer G Robinson
Jul 8, 2010·Expert Opinion on Drug Metabolism & Toxicology·Divya Samineni, Carl J Fichtenbaum
May 29, 2012·Biochemical Pharmacology·Emmanuelle Plée-GautierLaurent Corcos
Aug 27, 2009·Alimentary Pharmacology & Therapeutics·D A H ElfakiK D Lindor
May 30, 2009·Obesity·Cecilia Gómez-SantosMarta Garaulet
May 6, 2009·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·M A EdensR P Stolk
Jun 23, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Stephen A HarrisonMark S Sulkowski
May 25, 2013·Fundamental & Clinical Pharmacology·Thavarak OukRégis Bordet
Jul 11, 2012·International Journal of Cell Biology·Vincent BerezowskiJérôme Badaut
May 23, 2009·Pharmacology & Therapeutics·Karen E Porter, Neil A Turner
May 8, 2010·Respiratory Medicine·James D ChalmersAdam T Hill
Jul 19, 2011·The Journal of Infection·Vicente F Corrales-Medina, Daniel M Musher
Apr 17, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Richard P Phipps, Neil Blumberg
Apr 10, 2009·Menopause : the Journal of the North American Menopause Society·Thomas Dayspring
Jun 16, 2010·Biogerontology·Andrea CorsonelloFabrizia Lattanzio
Jun 16, 2009·Shock·A B Johan GroeneveldMelanie van der Heijden
Nov 23, 2012·Biologie aujourd'hui·Vincent BérézowskiRoméo Cecchelli
Mar 11, 2016·Chinese Medical Sciences Journal = Chung-kuo I Hsüeh K'o Hsüeh Tsa Chih·Li ShengChun-Guang Han

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.